Novo Nordisk As Stock Current Valuation
| NONOF Stock | USD 106.83 0.24 0.23% |
Valuation analysis of Novo Nordisk AS helps investors to measure Novo Nordisk's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novo pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Novo Nordisk AS. Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Pink Sheet. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 106.83 | Real 100.42 | Hype 106.83 |
The real value of Novo Pink Sheet, also known as its intrinsic value, is the underlying worth of Novo Nordisk AS Company, which is reflected in its stock price. It is based on Novo Nordisk's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk AS Company Current Valuation Analysis
Novo Nordisk's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Novo Nordisk Current Valuation | 292.82 B |
Most of Novo Nordisk's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Novo Nordisk AS has a Current Valuation of 292.82 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Novo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in current valuation category among its peers.
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Shares Owned By Institutions | 38.87 % | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Price To Earnings To Growth | 1.94 X | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 318.05 B | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Working Capital | 9.98 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.78 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.